Kottorou Anastasia E, Dimitrakopoulos Foteinos-Ioannis D, Antonacopoulou Anna G, Diamantopoulou Georgia, Tsoumas Dimitrios, Koutras Angelos, Makatsoris Thomas, Stavropoulos Michalis, Thomopoulos Konstantinos C, Hulbert Alicia, Tzelepi Vassiliki, Kalofonos Haralabos P
Clinical and Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, 26504 Rio, Greece.
Division of Gastroenterology, University Hospital of Patras, 26504 Rio, Greece.
Cancers (Basel). 2020 Apr 7;12(4):895. doi: 10.3390/cancers12040895.
Deregulation of the transcribed ultra-conserved regions (T-UCRs) Uc160, Uc283, and Uc346 has been reported in colorectal cancer (CRC) recently. Here, we investigated promoter methylation of these T-UCRs during the adenoma-carcinoma sequence and their clinical significance in CRC patients. Methylation levels were assessed in CRC, adenomas, infiltrated lymph nodes, and metastatic tissue specimens. In situ hybridization was performed in representative tissue specimens. T-UCRs expression levels were also evaluated in HT-29 colon cancer cells before and after the acquired resistance to 5-fluorouracil (5-FU) and oxaliplatin. A gradual increase in T-UCRs methylation levels from hyperplastic polyps to adenomas and to in situ carcinomas (ISC) and a gradual decrease from ISC to infiltrative and metastatic carcinomas was observed ( < 0.001 for Uc160 and Uc283, = 0.018 for Uc346). Uc160 and Uc283 methylation was associated with the grade of dysplasia in adenoma specimens ( = 0.034 and = 0.019, respectively). Furthermore, higher Uc160 methylation, mainly in stage III and IV patients, was related to improved overall survival (OS) in univariate (p = 0.009; HR, 0.366) and multivariate analysis (p = 0.005; HR, 0.240). Similarly, higher methylation of Uc283 was associated with longer OS (p = 0.030). Finally, T-UCRs expression was significantly reduced in HT-29 cells after resistance to chemotherapy. This study suggests that promoter methylation of Uc160, Uc283, and Uc346 is altered during CRC development and that Uc160 and Uc283 methylation may have prognostic significance for CRC patients.
最近有报道称,转录超保守区域(T-UCRs)Uc160、Uc283和Uc346在结直肠癌(CRC)中存在失调。在此,我们研究了这些T-UCRs在腺瘤-癌序列中的启动子甲基化情况及其在CRC患者中的临床意义。对CRC、腺瘤、浸润性淋巴结和转移组织标本的甲基化水平进行了评估。在代表性组织标本中进行了原位杂交。还评估了HT-29结肠癌细胞在获得对5-氟尿嘧啶(5-FU)和奥沙利铂的耐药性前后T-UCRs的表达水平。观察到从增生性息肉到腺瘤再到原位癌(ISC),T-UCRs甲基化水平逐渐升高,而从ISC到浸润性癌和转移性癌则逐渐降低(Uc160和Uc283,P<0.001;Uc346,P = 0.018)。Uc160和Uc283甲基化与腺瘤标本中的发育异常分级相关(分别为P = 0.034和P = 0.019)。此外,主要在III期和IV期患者中,较高的Uc160甲基化与单因素分析(P = 0.009;HR,0.366)和多因素分析(P = 0.005;HR,0.240)中总体生存率(OS)的改善相关。同样,较高的Uc283甲基化与较长的OS相关(P = 0.030)。最后,化疗耐药后HT-29细胞中T-UCRs的表达显著降低。这项研究表明,Uc160、Uc283和Uc346的启动子甲基化在CRC发展过程中发生改变,并且Uc160和Uc283甲基化可能对CRC患者具有预后意义。